Jeffrey Edwards
Director/Board Member en FIBROGEN, INC. .
Fortuna: 343 578 $ al 31/03/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Pyott | M | 70 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA.
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 26 años |
James Schoeneck | M | 66 | 14 años | |
George Lasezkay | M | 72 | 21 años | |
William Humphries | M | 57 | 21 años | |
Norman Schwartz | M | 74 | 35 años | |
David I. Stirling | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 años |
Arnold A. Pinkston | M | 65 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 13 años |
James Hall | M | 61 | 7 años | |
Clay Thorp | M | 55 | 12 años | |
F. Ball | M | 68 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 17 años |
Robert J. Schotzinger | M | 63 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 13 años |
Matthew Joseph Maletta | M | 52 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | - |
Craig Barbarosh | M | 57 | 5 años | |
Adrian Howd | M | 52 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
Andrew von Eschenbach | M | 82 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 13 años |
Christy Shaffer | M | 66 | 12 años | |
Gregory Hinckley | M | 77 | 41 años | |
Samuel Gesten | M | 62 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 3 años |
Raymond Diradoorian | M | 66 | 37 años | |
John Morberg | M | 60 | 3 años | |
Thane Wettig | M | 59 | 4 años | |
Philippe Drouet | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 3 años |
Melinda Litherland | F | 66 | 7 años | |
Nancy Miller-Rich | F | 65 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 3 años |
Timothy Ernst | M | 64 | 8 años | |
Suzanne Blaug | F | 66 | 5 años | |
Aoife Brennan | M | 48 | 4 años | |
Meichiel Keenan | F | - | 20 años | |
Allison Schwartz | F | 43 | 8 años | |
Nancy Hutson | M | 74 | 4 años | |
Nelson Obus | M | 77 | 6 años | |
Richard Croarkin | M | 69 | 8 años | |
May Kin Ho | M | 71 | 6 años | |
Alice Schwartz | F | 97 | 72 años | |
Katrina Houde | F | 66 | 5 años | |
Jeffrey Henderson | M | 59 | 9 años | |
Joshua Schechter | M | 51 | 4 años | |
Douglas Reed | M | 70 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 17 años |
Philip R. Tracy | M | 81 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 9 años |
Gerald Lema | M | 63 | 7 años | |
Benjamin Yerxa | M | 58 | 2 años | |
S. Torres | M | 61 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 13 años |
Benjamin Cravatt | M | 54 | 4 años | |
Christine Chung L. | F | 56 | 17 años | |
Steve Laninga | M | - | 4 años | |
Rahul Rajan Kaushik | M | - | - | |
Andrew Stapleton | M | 68 | - | |
Simon May | M | - | 10 años | |
Steve D. Weinstein | M | - |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
Kipling Thacker | M | 69 | 14 años | |
Louis J. DeGennaro | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
Jenny Kobin | F | - | - | |
Jonathan Seaton | M | 53 | - | |
Al Y. Lin | M | - | 25 años | |
Elias Kouchakji | M | 67 | 10 años | |
Michael D. Lowenstein | M | - | 21 años | |
Leanne C. Price | F | - | 25 años | |
Dennis Dougherty | M | 76 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
David DeLucia | M | - | - | |
Michael Crowley | M | 62 | 26 años | |
Scott Collins | M | - | 7 años | |
Edward Chung | M | - | - | |
Rick McElheny | M | - | 8 años | |
Kyle W. H. Chan | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 años |
Rajeev Dadoo | M | 54 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
Jackie Klecker | F | - | 14 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Douglas Ingram | M | 61 | 19 años | |
Daniel H. White | M | 57 | 8 años | |
Albert Bolles | M | 66 | 8 años | |
Thomas Kearns | M | 87 | 26 años | |
Thomas Byron Neff | M | 69 | 26 años | |
Brian McLaughlin | M | - | 1 años | |
Timothy Nelson | M | 60 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 8 años |
Ambrose Bailey | M | 60 | - | |
Robert Williamson | M | 58 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 1 años |
Rory Riggs | M | 71 | 29 años | |
Julian N. Stern | M | 99 | 25 años | |
Herb Boyer | M | 87 | 19 años | |
Vivid Sehgal | M | 56 | 8 años | |
Leslie B. Zacks | M | 55 | 4 años | |
Andrew Powell | M | 66 | 4 años | |
Maria Hilado | F | 59 | 4 años | |
Peter John McDonnell | M | 66 | 7 años | |
Catherine Sohn | M | 71 | 10 años | |
Pat Cotroneo | M | 60 | 21 años | |
Patricio Miguel Madero Blasquez | M | 74 | 20 años | |
Caroline F. van Hove | F | 43 | 16 años | |
John Goetz | M | 73 | 18 años | |
Kalevi Kurkijärvi | M | 72 | 25 años | |
Tonia Pankopf | F | 56 | 10 años | |
Toshinari Tamura | M | 80 | 12 años | |
Les Kaplan | M | 73 | 21 años | |
Deborah Neff | F | 71 | 6 años | |
Roberto Pedro Rosenkranz | M | 74 | 10 años | |
Louis Lavigne | M | 75 | 10 años | |
Michael R. Gallagher | M | 77 | - | |
Philippe Schaison | M | 62 | 3 años | |
Deborah Dunsire | M | 61 | 9 años | |
David Berk | M | 45 | 6 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 99 | 100.00% |
Bélgica | 0 | -.--% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jeffrey Edwards
- Red Personal